Regulation & Compliance

Payments firm REPAY is doubling down on its $372M KUBRA acquisition, but activist investor Veradace Partners is calling for the deal to be scrapped.

The insurer is offering at-home defibrillators and health tech, aiming to redefine its role from covering death to extending life. But what does it mean for you?

A family's personal journey with a rare disorder sparks a major investment in Quiver Bioscience's AI-powered therapy, aiming to treat Dup15q syndrome.

A new platform from cybersecurity veteran GIS QSP acts as a "flight recorder" for AI, offering cryptographic proof to unlock its use in regulated industries.

SoFi members can now send and receive money instantly, 24/7, a move that challenges traditional banking and sets a new standard for real-time payments.

GoldenTree's oversubscribed $3B fund close highlights a major shift as institutional investors seek flexible, high-yield private credit strategies.

Cybersecurity firm Doppel is one of the first 350 companies globally to achieve the new ISO 42001 standard for responsible AI, raising the bar for trust.

With NHS lists at 7.4M and implants costing a year's salary, half a million Brits now fly to Türkiye for dental care. Is it a perfect solution or a risky bet?

A Dallas emergency room adopts a new name, ER of White Rock, signaling a hyper-local focus amid the complex landscape of freestanding emergency care.

New data shows first-in-class drug tegavivint successfully inhibits the Wnt pathway, a driver in 30% of solid tumors, offering hope for tough cancers.

A new platform from BEO Investments uses AI to connect disparate SEC filings, promising unprecedented transparency into who is raising and deploying capital.

Auxly Cannabis Group lost its bid for Ayurcann but secured a profitable backup role, showcasing a shrewd strategy in Canada's consolidating cannabis market.

With deep D.C. experience, Scott Dziengelski takes the helm at NABH, poised to tackle pressing issues like parity, workforce, and the addiction crisis.

VITAL MedTech unveils a bold vertical integration strategy, leveraging its parent's semiconductor mastery to build imaging systems from raw materials to final scans.

IVY Rx unveils its 2026 compounded GLP-1 program with clear pricing, but operates in a market facing intense FDA warnings and regulatory uncertainty.

Replimune halts a promising cancer therapy and cuts jobs after a stunning FDA rejection, citing a 'failed' system and inconsistent regulatory process.

A jury found Abbott's Similac caused a fatal gut disease in premature infants, igniting a legal firestorm over what the formula giant knew and when.

A Chicago jury found Abbott liable for infants' injuries from Similac, adding to a wave of lawsuits over the deadly intestinal disease NEC.

As Origin Bancorp prepares its Q1 2026 results, investors are watching for clues on regional economic health and the impact of a shifting rate environment.

Forbes named Matt Gulbransen Minnesota's #1 wealth advisor. We explore the rigorous process behind the rank and the model that builds trust with the wealthy.